We specialize in rapid registration and distribution excellence that only takes 30-90 days to gain market access in Macau with a 100% success rate. This expedited process not only speeds up market access but allows us to quickly respond to patient needs and gain a competitive edge in the pharmaceutical market. Early access to treatment for patients suffering from conditions with limited options underscores ACA Pharma’s commitment to innovative healthcare solutions.

Partnership

Registration

Marketing

Distribution

Pediatric and Clinically Urgent Medications:

• Upon successful registration in Macau, these drugs can quickly access major hospitals in Beijing, Shanghai, Tianjin, Hainan, and Chongqing, as well as the top thirty-three pediatric hospitals nationwide, which treat almost 100% of China’s pediatric rare disease patients. Classified as clinically urgent and irreplaceable, these medications benefit from a streamlined approval process, entering leading hospitals without the need for national registration or clinical trials.

Fast-Track National Approval:

• Leveraging initial real-world data collected after Macau registration, national registration is typically completed within 3-6 months for Pediatric Orphan Drugs and 6-12 months for Clinically Urgent Medicines. This streamlined process ensures timely access to critical treatments for patients in need.

Media Coverage for Broader Awareness:

• Extensive media coverage ensures patients across the country who can afford out-of-pocket treatments are informed and can receive timely medical assistance.